{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:20:54Z","timestamp":1772130054636,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["BID 1728 OC.AR"],"award-info":[{"award-number":["BID 1728 OC.AR"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010253","name":"Secretar\u00eda de Ciencia y T\u00e9cnica, Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["20120130101305BA"],"award-info":[{"award-number":["20120130101305BA"]}],"id":[{"id":"10.13039\/501100010253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010253","name":"Secretar\u00eda de Ciencia y T\u00e9cnica, Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["PICT 2015\u20132594"],"award-info":[{"award-number":["PICT 2015\u20132594"]}],"id":[{"id":"10.13039\/501100010253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 GM110702"],"award-info":[{"award-number":["P30 GM110702"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.neuropharm.2019.107922","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:18:30Z","timestamp":1577103510000},"page":"107922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo"],"prefix":"10.1016","volume":"165","author":[{"given":"Veronica","family":"Bisagno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Alejandra","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Sanz Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Urbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1367-3071","authenticated-orcid":false,"given":"Edgar","family":"Garcia-Rill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.107922_bib1","author":"Acharya"},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107922_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-016-1587-4","article-title":"ALS and FTD: an epigenetic perspective","volume":"132","author":"Belzil","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2019.107922_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neuroscience.2018.03.022","article-title":"Effects of class II-selective histone deacetylase inhibitor on neuromuscular function and disease progression in SOD1-ALS mice","volume":"379","author":"Buonvicino","year":"2018","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.neuropharm.2019.107922_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e02265","article-title":"Proteomic measures of gamma oscillations","volume":"5","author":"Byrum","year":"2019","journal-title":"Heliyon"},{"issue":"5942","key":"10.1016\/j.neuropharm.2019.107922_bib5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.neuropharm.2019.107922_bib6","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/1078-0432.CCR-07-4836","article-title":"Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma","volume":"14","author":"Dalgard","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2019.107922_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0167-8140(95)01581-Z","article-title":"Nicotinamide pharmacokinetics in patients","volume":"36","author":"Dragovic","year":"1995","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.neuropharm.2019.107922_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1152\/jn.00828.2014","article-title":"Modulation of gamma oscillations in the pedunculopontine nucleus (PPN) by neuronal calcium sensor protein-1 (NCS-1): relevance to schizophrenia and bipolar disorder","volume":"113","author":"D'Onofrio","year":"2015","journal-title":"J. Neurophysiol."},{"issue":"19","key":"10.1016\/j.neuropharm.2019.107922_bib9","doi-asserted-by":"crossref","first-page":"7332","DOI":"10.1523\/JNEUROSCI.2174-14.2015","article-title":"Sp3\/REST\/HDAC1\/HDAC2 complex represses and Sp1\/HIF-1\/p300 complex activates ncx1 gene transcription, in brain ischemia and in ischemic brain preconditioning, by epigenetic mechanism","volume":"35","author":"Formisano","year":"2015","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107922_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDAC, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res."},{"key":"10.1016\/j.neuropharm.2019.107922_bib11","series-title":"Waking and the Reticular Activating System","first-page":"330","author":"Garcia-Rill","year":"2015"},{"key":"10.1016\/j.neuropharm.2019.107922_bib12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/sleep\/30.11.1405","article-title":"Electrical coupling: novel mechanism for sleep-wake control","volume":"30","author":"Garcia-Rill","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2019.107922_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/sleep\/31.5.673","article-title":"The developmental decrease in REM sleep: the role of transmitters and electrical coupling","volume":"31","author":"Garcia-Rill","year":"2008","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.neuropharm.2019.107922_bib14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00702-015-1485-2","article-title":"Implications of gamma band activity in the pedunculopontine nucleus","volume":"123","author":"Garcia-Rill","year":"2016","journal-title":"J. Neural Transm."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.107922_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/toxsci\/kfw157","article-title":"MC1568 inhibits thimerosal-induced apoptotic cell death by preventing HDAC4 up-regulation in neuronal cells and in rat prefrontal cortex","volume":"154","author":"Guida","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107922_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107922_bib17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12185-016-2008-0","article-title":"Histone deacetylase inhibitors in multiple myeloma: from bench to bedside","volume":"104","author":"Harada","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107922_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/icb.2011.99","article-title":"Lysine acetylation in obesity, diabetes and metabolic disease","volume":"90","author":"Iyer","year":"2012","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107922_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12035-017-0735-8","article-title":"Histone deacetylase inhibitor entinostat (MS-275) restores anesthesia-induced alteration of inhibitory synaptic transmission in the developing rat Hippocampus","volume":"55","author":"Joksimovic","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2019.107922_bib20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1460-9568.2011.07766.x","article-title":"Mechanism behind gamma band activity in the pedunculopontine nucleus (PPN)","volume":"34","author":"Kezunovic","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107922_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1152\/jn.00677.2011","article-title":"Gamma band activity in the developing parafascicular nucleus (Pf)","volume":"107","author":"Kezunovic","year":"2012","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2019.107922_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fneur.2013.00176","article-title":"Muscarinic modulation of high frequency oscillations in pedunculopontine neurons","volume":"4","author":"Kezunovic","year":"2013","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107922_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5607\/en.2019.28.4.504","article-title":"HDAC inhibition by valproic acid induces neuroprotection and improvement of PD-like behaviors in LRRK2 R1441G transgenic mice","volume":"28","author":"Kim","year":"2019","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.neuropharm.2019.107922_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.nbd.2012.08.018","article-title":"Targeted acetylation of NF-kappaB\/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window","volume":"49","author":"Lanzillotta","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.107922_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.neuroscience.2019.03.033","article-title":"HDAC2, but not HDAC1, regulates Kv1.2 expression to mediate neuropathic pain in CCI rats","volume":"408","author":"Li","year":"2019","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107922_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107922_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2016.12.006","article-title":"Targeting class I histone deacetylases in a \"complex\" environment","volume":"38","author":"Millard","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2019.107922_bib28","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1091\/mbc.11.6.2069","article-title":"Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells","volume":"11","author":"Qiu","year":"2000","journal-title":"Mol. Biol. Cell"},{"issue":"10","key":"10.1016\/j.neuropharm.2019.107922_bib29","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1124\/dmd.104.000638","article-title":"Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice","volume":"32","author":"Sanderson","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107922_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174763","article-title":"Amelioration of cognitive impairments in APPswe\/PS1dE9 mice is associated with metabolites alteration induced by total salvianolic acid","volume":"12","author":"Shen","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107922_bib31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1152\/jn.00242.2010","article-title":"Gamma band unit activity and population responses in the pedunculopontine nucleus","volume":"104","author":"Simon","year":"2010","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2019.107922_bib32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2014.12.004","article-title":"Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders","volume":"149","author":"Singewald","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.neuropharm.2019.107922_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1586\/era.10.62","article-title":"Nonhistone protein acetylation as cancer therapy targets","volume":"10","author":"Singh","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"9","key":"10.1016\/j.neuropharm.2019.107922_bib34","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuropharm.2019.107922_bib35","doi-asserted-by":"crossref","first-page":"13156","DOI":"10.1038\/s41598-018-31584-2","article-title":"Class II histone deacetylases require P\/Q-type Ca2+ channels and CaMKII to maintain gamma oscillations in the pedunculopontine nucleus","volume":"8","author":"Urbano","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.107922_bib36","article-title":"Gamma oscillations in the pedunculopontine nucleus are regulated by F-actin: neuroepigenetic implications","author":"Urbano","year":"2019","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.neuropharm.2019.107922_bib37","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1460-9568.2008.06576.x","article-title":"Pedunculopontine and laterodorsal tegmental nuclei contain distinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat","volume":"29","author":"Wang","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107922_bib38","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1152\/jn.01143.2009","article-title":"Cholinergic modulation of fast inhibitory and excitatory transmission to pedunculopontine thalamic projecting neurons","volume":"103","author":"Ye","year":"2010","journal-title":"J. Neurophysiol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819304939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819304939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:58:52Z","timestamp":1758437932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819304939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":38,"alternative-id":["S0028390819304939"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107922","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107922"}}